=> fil hcaplu FILE 'HCAPLUS' ENTERED AT 16:40:42 ON 20 AUG 2001 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 20 Aug 2001 VOL 135 ISS 9 FILE LAST UPDATED: 19 Aug 2001 (20010819/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=> d stat que

L1 3 SEA FILE=REGISTRY SYIVLCIE/SQSP NOT NSFMTSFSK/SQSP

L2 4 SEA FILE=HCAPLUS L1

=> d ibib abs hitrn 12 1-4

L2 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2001 ACS ACCESSION NUMBER: 2000:814324 HCAPLUS

DOCUMENT NUMBER: 134:505

TITLE: Antiangiogenic endostatin peptides, endostatin

variants and methods of use

INVENTOR(S): Vuori, Kristiina

PATENT ASSIGNEE(S): The Burnham Institute, USA SOURCE: PCT Int. Appl., 146 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2000067771 A1 20001116 WO 2000-US12063 20000502

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB,

```
GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO,
             NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT,
             TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                        US 1999-132907
                                                          P 19990506
                                        US 1999-353333
                                                         A2 19990714
AB
     The invention provides an endostatin peptide having at least 4-7
     endostatin amino acid residues contg. substantially the amino acid
     sequence of RLQD, RAD, DGK/R, or a functional equiv. thereof. The
     invention also provides an endostatin variant contg. the amino acid
     sequence RGD, or a functional fragment thereof. Methods of inhibiting
     angiogenesis are also provided.
IT
     307924-80-7
     RL: BOC (Biological occurrence); PRP (Properties); BIOL (Biological
     study); OCCU (Occurrence)
        (antiangiogenic endostatin peptides, endostatin variants and methods of
        use)
REFERENCE COUNT:
REFERENCE(S):
                         (1) Brooks; US 5753230 A 1998 HCAPLUS
                         (2) Koivunen, E; Journal of Biological Chemistry 1993,
                             V268(27), P20205 HCAPLUS
                         (3) La Jolla Cancer Research Foundation; WO 9514714 A1
                             1995 HCAPLUS
                         (4) Nutt; US 5061693 A 1991 HCAPLUS
                         (5) Oh, S; Proc Natl Acad Sci USA 1994, V91, P4229
                             HCAPLUS
                         ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2001 ACS
L2
ACCESSION NUMBER:
                         2000:434233 HCAPLUS
DOCUMENT NUMBER:
                         133:79332
TITLE:
                         Carrier-DNA complexes containing DNA encoding
                         anti-angiogenic peptides and their use in gene therapy
INVENTOR(S):
                         Mixson, A. James
PATENT ASSIGNEE(S):
                         USA
SOURCE:
                         U.S., 30 pp., Cont.-in-part of U.S. 5,815,216.
                         CODEN: USXXAM
DOCUMENT TYPE:
                         Patent
LANGUAGE:
                         English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
    PATENT NO.
                      KIND DATE
                                           APPLICATION NO.
                                                            DATE
    US 6080728
                            20000627
                      Α
                                           US 1997-985526
                                                            19971205
    EP 819758
                      A2
                            19980121
                                           EP 1997-112154
                                                            19970716
    EP 819758
                            19980204
                      А3
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    EP 921193
                      A1
                          19990609
                                           EP 1998-100135
                                                            19980107
```

```
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
      JP 11187886
                      A2 19990713
                                          JP 1998-201996 19980716
 PRIORITY APPLN. INFO.:
                                        US 1996-680845 A2 19960716
                                        EP 1997-112154
                                                       A 19970716
                                        US 1997-985526 A 19971205
 AΒ
     Carrier complexes comprising DNA encoding an anti-angiogenic gene or
     peptide and optionally a further DNA encoding a tumor suppressor protein
     are described. When administered to a subject bearing a tumor, the
     complexes can inhibit growth of the tumor.
     226938-38-1, Endostatin (human fragment)
 IT
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
      (Uses)
         (amino acid sequence; carrier-DNA complexes contg. DNA encoding
        anti-angiogenic.peptides and their use in gene therapy)
 REFERENCE COUNT:
                         40
REFERENCE(S):
                         (1) Anon; EP 0443404 A1 1991 HCAPLUS
                         (2) Anon; WO 9202240 1992 HCAPLUS
                         (3) Anon; WO 9316716 1993 HCAPLUS
                         (4) Anon; WO 9316718 1993 HCAPLUS
                         (5) Anon; WO 9529242 1995 HCAPLUS
                         ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER:
                    2000:62891 HCAPLUS
DOCUMENT NUMBER:
                         132:103744
TITLE:
                         Cloning of cDNA for human endostatin and use for
                         inhibition of angiogenesis
INVENTOR(S):
                        Xu, Genxing; Ren, Mindong; Xu, Lin
                     Peop. Rep. China
PATENT ASSIGNEE(S):
SOURCE:
                        Faming Zhuanli Shenqing Gongkai Shuomingshu, 6 pp.
                        CODEN: CNXXEV
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                        Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
     PATENT NO.
                 KIND DATE
                                          APPLICATION NO. DATE
                     ____
                           -----
                                          -----
     CN 1177005 A 19980325
CN 1060521 B 20010110
     CN 1177005
                                          CN 1997-107112 19970910
AB
     Described is a method of cloning the cDNA for human liver endostatin by
     PCR using a pair of primers derived from the cDNA encoding human collagen
     type XVIII (1503-2055 cDNA fragment). Endostatin is useful for the
     treatment of tumors by inhibiting angiogenesis.
IT
    255811-03-1
     RL: PRP (Properties)
        (unclaimed sequence; cloning of cDNA for human endostatin and use for
       inhibition of angiogenesis)
    ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:375339 HCAPLUS
```

Delivery of anti-angiogenic genes to a tumor in vivo

131:28626

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

and their use in gene therapy

Mixson, Archibald James

PATENT ASSIGNEE(S): USA

SOURCE:

Eur. Pat. Appl., 46 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

LANGUAGE:

•

Patent English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION: ...

PATENT NO.	KIND DATE	APPLICATION NO. DATE	
EP 921193	A1 19990609		
R: AT, E	BE, CH, DE, DK, ES, SI, LT, LV, FI, RO	FR, GB, GR, IT, LI, LU, NL, SE, M	C, PT,
US 6080728 PRIORITY APPLN. IN	A 20000627	US 1997-985526 19971205 US 1997-985526 A 19971205	
•		US 1996-680845 A2 19960716	

EP 1997-112154 A 19970716 The invention relates to the delivery of anti-angiogenic genes or DNA AB encoding anti-angiogenic peptides to a tumor in vivo, preferably by injection, and expression of the DNA in order to inhibit tumoral growth. Provided are carrier: DNA complexes which comprise cationic polymers or cationic liposomes and DNA encoding at least one anti-angiogenic protein/peptide, optionally together with further DNA encoding a tumor suppressor protein, esp. p53. When administered to a subject bearing a tumor, the complexes can inhibit growth of the tumor.

IT 226938-38-1P, Endostatin (human fragment) RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; delivery of anti-angiogenic genes to a tumor in vivo and their use in gene therapy)

REFERENCE COUNT:

REFERENCE(S):

- (1) Chiron Viagene Inc; WO 9621416 A 1996 HCAPLUS
- (2) Lescon-Wood, L; Human Gene Therapy 1995, V6(4), P395 HCAPLUS
- (3) Mixson, A; EP 0819758 A 1998 HCAPLUS
- (4) The Children's Medical Center Corporation; WO 9529242 A 1995 HCAPLUS
- (5) Weinstat-Saslow, D; Cancer Research 1994, V54, P6504 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil reg FILE 'REGISTRY' ENTERED AT 16:41:24 ON 20 AUG 2001 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 19 AUG 2001 HIGHEST RN 351975-45-6 DICTIONARY FILE UPDATES: 19 AUG 2001 HIGHEST RN 351975-45-6

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> d rn cn lc nte sql kwic can tot ll

```
L1 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2001 ACS
```

RN 307924-80-7 REGISTRY

CN L-Methionine, L-.alpha.-glutamyl-L-seryl-L-tyrosyl-L-cysteinyl-L-.alpha.glutamyl-L-threonyl-L-tryptophyl-L-arginyl-L-threonyl-L-.alpha.-glutamyl-Lthreonyl-L-threonylglycyl-L-alanyl-L-threonylglycyl-L-glutaminyl-L-alanylL-seryl-L-seryl-L-leucyl-L-leucyl-L-serylglycyl-L-arginyl-L-leucyl-Lleucyl-L-.alpha.-glutamyl-L-glutaminyl-L-lysyl-L-alanyl-L-alanyl-L-seryl-Lcysteinyl-L-histidyl-L-asparaginyl-L-seryl-L-tyrosyl-L-isoleucyl-L-valyl-Lleucyl-L-cysteinyl-L-isoleucyl-L-.alpha.-glutamyl-L-asparaginyl-L-seryl-Lphenylalanyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 11: PN: WO0067771 SEQID: 21 claimed protein

LC STN Files: CA, CAPLUS, TOXLIT

SQL 48

SEQ 1 ESYCETWRTE TTGATGQASS LLSGRLLEQK AASCHNSYIV LCIENSFM

HITS AT: 37-44

REFERENCE 1: 134:505

L1 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2001 ACS

RN 255811-03-1 REGISTRY

CN 4: PN: CN1177005 PAGE: 4 unclaimed sequence (9CI) (CA INDEX NAME)

LC STN Files: CA, CAPLUS, TOXLIT

NTE

type ----- location ----- description

uncommon Aaa-181

SQL 181

SEQ 151 SLLSGRLLEQ KAASCHNSYI VLCIENSFMT X

=== ====

HITS AT: 168-175

REFERENCE 1: 132:103744

L1 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2001 ACS

RN 226938-38-1 REGISTRY

CN Endostatin (human fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 31: PN: US6080728 SEQID: 36 claimed protein

M. Smith 308-3278

Endostatin (synthetic 185-amino acid fragment) STN Files: CA, CAPLUS, TOXLIT, USPATFULL LC

SQL 185

151 SSLLSGRLLE QRAASCHDSY IVLCIENSFM TSFSR SEQ

== =====

HITS AT: 169-176

REFERENCE 1: 133:79332

REFERENCE 2: 131:28626